Misonix, Inc. announced the appointment of Gwen Watanabe to its Board of Directors. Ms. Watanabe replaces John Gildea, the founding principal of Gildea Management Co., who has retired from his position on the Board of Directors. Gwen Watanabe has over 24 years of financial and executive management experience in the medical device industry. Ms. Watanabe presently serves as the vice president of global corporate development, strategy, and strategic partnerships for Teleflex Incorporated, a global provider of medical technology products, where she also serves as a member of the executive leadership team, reporting to Teleflex’s CEO. In her role at Teleflex, she is responsible for worldwide corporate strategy and mergers and acquisitions. Prior to Teleflex, Ms. Watanabe served as president and chief executive officer of medical device start-up Hotspur Technology, Inc., where she led the company from initial idea and design concept in 2009 through commercial release before negotiating the successful sale of the business to Teleflex in 2012. From 2004 to 2009, Ms. Watanabe served as chief business officer and chief financial officer of Nellix Endovascular, Inc., a medical device start-up that she co-founded, where she successfully raised venture capital financing and led a broad range of strategic initiatives that resulted in the acquisition of the company by Endologix. Earlier in her career, she served as a business development manager at Bacchus Vascular, Inc. (acquired by Covidien) and a project engineer at Aneurx, Inc. (acquired by Medtronic). In addition, Ms. Watanabe was a general partner at Saratoga Ventures V, L.P. and Saratoga Ventures VI, L.P., which were all medical device venture funds.